AI Terminal
Xbrane Biopharma
Declaration of Voting Results & Voting Rights Announcements • Oct 31, 2023
3128_rns_2023-10-31_5be2ffd2-41a0-42e7-9227-dd1644239581.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.
The number of shares and votes in Xbrane have changed following the issue of 79,252 shares during October through exercise of warrants under LTIP 2020, adopted at the annual general meeting 2020.
As of October 31, 2023, the total number of shares and votes in the Company amounts to 29,810,364. The Company's registered share capital amounts to about SEK 6,683,068.
Contacts
Martin Åmark, CEO M: +46 76 309 37 77 E: [email protected]
Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: [email protected]
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-10-31 13:00 CET.
Attachments
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.